Key Takeaways Novo Nordisk signed a $2.1B agreement with Omeros for rights to develop and market zaltenibart.Omeros gains$340M upfront and milestone payments, plus royalties on potential future sales.The deal supports NVO's push beyond GLP-1 drugs toward rare blood and kidney disorder therapies.Novo Nordisk (NVO) and Omeros Corporation (OMER) have announced the signing of a definitive asset purchase and license agreement for zaltenibart (formerly OMS906), a clinical-stage candidate targeting rare blood and ...